ARWRARROWHEAD PHARMACEUTICALS, INC.
Pharmaceutical Preparations
- Revenue
- $829M
- 23258% YoY
- Operating margin
- 11.9%
- 100% YoY
- EBITDA
- $121M
- 121% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear8% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $138M | $243M | $241M | $4M | $829M | 23258% |
| Operating income | −$149M | −$179M | −$205M | −$601M | $98M | 116% |
| Net income | −$141M | −$176M | −$205M | −$599M | −$2M | 100% |
| Operating cash flow | $171M | −$136M | −$154M | −$463M | $180M | 139% |
| Capex | $24M | $53M | $177M | $141M | $23M | 84% |
| Stock-based comp | $77M | $121M | $78M | $74M | $63M | 14% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.